|
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
RECRUITINGPhase 3Sponsored by Qilu Pharmaceutical Co., Ltd.
Actively Recruiting
PhasePhase 3
SponsorQilu Pharmaceutical Co., Ltd.
Started2026-10-27
Est. completion2029-03-15
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07802821
Summary
This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age ≥18 years. 2. Participants with histologically or cytologically confirmed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) per the Veterans Administration Lung Cancer Study Group (VALG) staging system. 3. No prior systemic treatment for ES-SCLC. 4. At least one extracranial measurable lesion according to RECIST v1.1. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, without deterioration within 2 weeks prior to the first dose of study treatment. 6. Life expectancy ≥12 weeks. 7. Has adequate organ function. 8. Male and female participants of reproductive/childbearing potential must agree to avoid pregnancy. 9. Voluntarily sign the written informed consent form and comply with the protocol requirements. Exclusion Criteria: 1. Has received or undergoing any of the following treatment: Previous or current treatment with B7-H3 targeted therapy. Previous or current treatment with topoisomerase I inhibitors. 2. Participants with transformed Non-Small Cell Lung Cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation-positive NSCLC that has transformed to SCLC, or mixed SCLC-NSCLC histology. 3. Presence with active brain metastases, leptomeningeal metastasis, brainstem metastasis or spinal cord compression. 4. Radiotherapy with a limited field of radiation within 2 weeks prior to the study treatment; more than 30% of the bone marrow irradiation or large-scale radiotherapy within 4 weeks prior to study treatment. 5. Major surgery within 4 weeks prior to the study treatment. 6. Unresolved AEs ≥ Grade 2 (CTCAE v6.0) from prior therapy. 7. Previous or concurrent primary malignancies. 8. History of severe heart disease or cerebrovascular disease. 9. History of Severe or uncontrolled hypertension or diabetes mellitus. 10. Severe infection within 4 weeks prior to study treatment; or uncontrolled active infection at screening. 11. Known or suspected interstitial lung disease/non-infectious pneumonitis; or other moderate to severe pulmonary diseases that significantly impair respiratory function and may interfere with the detection or management of drug-related pulmonary toxicity. 12. Known history of pre-existing or newly diagnosed autoimmune disease. 13. History of severe neuropathy or mental disorders. 14. History of severe hypersensitivity reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to study drugs or any components of the study drugs. 15. Unlikely to comply with study procedures and requirements in the opinion of the investigator. 16. Any disease or condition that, in the opinion of the investigator, would compromise participant safety or interfere with study assessments.
Conditions3
CancerExtensive Stage-small Cell Lung CancerLung Cancer
Interventions6
Related trials
- A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors — Mabwell (Shanghai) Bioscience Co., Ltd.
- A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer — Shanghai Jiao Tong University School of Medicine
- A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer — Xianglin Yuan
- A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy — Tianjin Medical University Cancer Institute and Hospital
- A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies — First Affiliated Hospital of Fujian Medical University
- A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) — Sichuan Baili Pharmaceutical Co., Ltd.
- A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) — Sichuan Baili Pharmaceutical Co., Ltd.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorQilu Pharmaceutical Co., Ltd.
Started2026-10-27
Est. completion2029-03-15
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07802821